Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?

被引:17
作者
Tazza, F. [1 ]
Lapucci, C. [1 ,2 ]
Cellerino, M. [1 ]
Boffa, G. [1 ]
Novi, G. [3 ]
Poire, I [3 ]
Mancuso, E. [1 ]
Bruschi, N. [1 ]
Sbragia, E. [1 ]
Laroni, A. [1 ,3 ]
Capello, E. [1 ,3 ]
Inglese, M. [1 ,3 ]
机构
[1] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy
[2] Osped Policlin San Martino IRCCS, Lab Expt Neurosci, Genoa, Italy
[3] Osped Policlin San Martino IRCCS, Genoa, Italy
关键词
Multiple sclerosis; Treatment; Ocrelizumab; COVID-19; Efficacy; Safety;
D O I
10.1016/j.jns.2021.117501
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
During SARS-CoV-2 pandemic, we adopted a personalized delayed protocol for ocrelizumab infusions in Relapsing Remitting Multiple Sclerosis (RRMS) patients according to the national recommendations. Out of the 83 RRMS patients whose infusion was scheduled between March and December 2020, 56 patients experienced a delay in treatment based on MS severity and SARS-CoV2 infection risk profile. In most cases, the immunophenotype was performed monthly to guide re-infusions. Specifically, B CD19 + cells repopulation rate was monitored. Mean infusion delay was 103,1 [SD 40,6] days, and none of the patients presented relapses or active disease at MRI at the end of the observation period. Treatment naive status and the interval between immunophenotyping and the last ocrelizumab infusion were predictors of earlier B CD19 + cells repopulation. Two patients contracted SARS-CoV2 with complete recovery. Definitive data about Sars-Cov2 vaccine efficacy in patients treated with ocrelizumab are still lacking. Our findings suggest that a personalized treatment with a delayed infusion schedule does not compromise ocrelizumab short-term efficacy and may help to lengthen the therapeutic window for an effective response to SARS-CoV2 vaccine.
引用
收藏
页数:4
相关论文
共 50 条
[41]   The SARS-CoV-2 pandemic and asthma: What we have learned and what is still unknown [J].
Mcphee, Christa ;
Yevdokimova, Kateryna ;
Rogers, Linda ;
Kraft, Monica .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 152 (06) :1376-1381
[42]   COVID-19 Pandemic and Eating Disorders: What Can We Learn About Psychopathology and Treatment? A Systematic Review [J].
Monteleone, Alessio Maria ;
Cascino, Giammarco ;
Barone, Eugenia ;
Carfagno, Marco ;
Monteleone, Palmiero .
CURRENT PSYCHIATRY REPORTS, 2021, 23 (12)
[43]   COVID-19 Pandemic and Eating Disorders: What Can We Learn About Psychopathology and Treatment? A Systematic Review [J].
Alessio Maria Monteleone ;
Giammarco Cascino ;
Eugenia Barone ;
Marco Carfagno ;
Palmiero Monteleone .
Current Psychiatry Reports, 2021, 23
[44]   Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases [J].
Nistri, Riccardo ;
Barbuti, Elena ;
Rinaldi, Virginia ;
Tufano, Laura ;
Pozzilli, Valeria ;
Ianniello, Antonio ;
Marinelli, Fabiana ;
De Luca, Giovanna ;
Prosperini, Luca ;
Tomassini, Valentina ;
Pozzilli, Carlo .
FRONTIERS IN NEUROLOGY, 2021, 12
[45]   CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis [J].
Baker, David ;
MacDougall, Amy ;
Kang, Angray S. ;
Schmierer, Klaus ;
Giovannoni, Gavin ;
Dobson, Ruth .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
[46]   Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients [J].
Georgieva, Zoya G. ;
Doffinger, Rainer ;
Kumararatne, Dinakantha ;
Coles, Alasdair J. ;
McCarthy, Claire .
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (07) :1126-1130
[47]   Virtual nutrition consultation: what can we learn from the COVID-19 pandemic? [J].
Kaufman-Shriqui, Vered ;
Sherf-Dagan, Shiri ;
Boaz, Mona ;
Birk, Ruth .
PUBLIC HEALTH NUTRITION, 2021, 24 (05) :1166-1173
[48]   Long T2 water in multiple sclerosis: What else can we learn from multi-echo T2 relaxation? [J].
C. Laule ;
I. M. Vavasour ;
S. H. Kolind ;
A. L. Traboulsee ;
G. R. W. Moore ;
D. K. B. Li ;
A. L. MacKay .
Journal of Neurology, 2007, 254 :1579-1587
[49]   Long T2 water in multiple sclerosis:: What else can we learn from multi-echo T2 relaxation? [J].
Laule, Cornelia ;
Vavasour, Irene M. ;
Kolind, Shannon H. ;
Traboulsee, Anthony L. ;
Moore, G. R. Wayne ;
Li, David K. B. ;
MacKay, Alex L. .
JOURNAL OF NEUROLOGY, 2007, 254 (11) :1579-1587
[50]   Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study [J].
Manzano, Giovanna S. ;
Rice, Dylan R. ;
Klawiter, Eric C. ;
Matiello, Marcelo ;
Gillani, Rebecca L. ;
Tauhid, Shahamat S. ;
Bakshi, Rohit ;
Mateen, Farrah J. .
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (07) :1146-1150